Media release from the University of Otago
Friday 30 April 2021
Aotearoa achieved a major milestone in sexual and reproductive health and rights with the decriminalisation of abortion, but a University of Otago academic argues abortion care is still not being provided within the full extent of the law.
Emma Macfarlane, a Lecturer in the Department of Women's and Children's Health, believes little has changed in the way abortion services are organised in the year since the Abortion Legislation Act 2020 came in. She also argues we are yet to realise the full extent of abortion care within a decriminalised environment.
Apr 26, 2021
The Department of Health must take "concrete steps" towards commissioning full abortion services in NI before the summer, a government minister has said.
Robin Walker said the secretary of state stands ready to act if significant progress is not made.
22 April 2021
On 18th March 2021, FIGO – in collaboration with the Centre for Reproductive Rights and Ipas – organised a discussion on ‘Access to medical abortion and self –managed abortion. Key insights from health workers and human rights advocates: on guaranteeing human rights’ with United Nations treaty monitoring committee members and Special Procedures mandate holders.
These elected UN experts have a responsibility to interpret human rights treaties, which includes monitoring states’ compliance with their legally binding human rights obligations and recommendations from UN experts. This includes reproductive rights and access to safe abortion. The UN experts do this by conducting fact-finding missions and issuing progress reports and statements, in addition to conducting review meetings with governments to assess their progress.
BY ABIGAIL ABRAMS
APRIL 13, 2021
The Biden Administration is removing restrictions on mailing abortion pills during the COVID-19 pandemic, a reversal from the Trump Administration’s policy that marks a new phase in the national debate over abortion rights.
The move temporarily changes longstanding Food and Drug Administration (FDA) rules governing mifepristone—one of two drugs used to terminate early pregnancies—that required patients to pick up the pills in-person from a medical provider. Acting FDA Commissioner Janet Woodcock sent a letter to the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine on Monday saying that her agency reviewed recent evidence and found that using telemedicine to provide abortion pills would not increase risks and would help patients avoid potential exposure to COVID-19.
March 9, 2021
Some of Onikepe Owolabi's most vivid memories of medical school in her native Nigeria are of the teenage girls she saw in the emergency room of a rural hospital with complications from an unsafe abortion — painful infections that, if left untreated, can lead to permanent disability or even death.
Each time, Owolabi, now a senior research scientist with the Guttmacher Institute, a nonprofit reproductive rights organization in the U.S. that supports abortion rights, assisted doctors in promptly providing the girls with a group of essential obstetric services known collectively as "post-abortion care," or PAC.
I deliver my patients' babies when needed, and perform their abortions when needed. Thankfully, my state treats all health care like health care.
Dr. Katherine Brown, Opinion contributor
Mar 7, 2021
I walk into the room and greet my patient with a smile. Six months earlier, I delivered her first baby by cesarean section after a long labor.
“How are you?” I ask. She assures me that she is doing fine, her daughter is thriving. She quickly takes out her phone and flips through a few recent photos. She smiles at me and tells me that she is just not ready for another baby. My patient is pregnant again and has made the decision to have an abortion. Just as I did when I delivered her daughter, I strive to hold a space of dignity and respect. I hold space for her and her emotions. I recognize that for her, she is making a difficult decision, but is doing so out of love and compassion.
기자명 Kim Chan-hyuk
Hyundai Pharm made it official that it will supply Mifegyne, an abortive drug, in Korea. Industry watchers said the supply could open ways for medication abortion.
However, as the company is preparing for the regulator’s preliminary review before seeking the nod, it will take a considerable time until a pregnant woman gets a Mifegyne prescription, observers said.
LEAH COPLON AND CLAIRE BRINDIS , Newsweek
Last year, over concerns of exposure to COVID-19, a federal judge ended the U.S. Food and Drug Administration's requirement that mifepristone, a medication necessary to terminate an early pregnancy, must be obtained directly from a hospital or provider's office.
On January 12, the Supreme Court reinstated that requirement, over the objection of medical organizations. The ruling put us right back where we were: Among the 20,000 medications regulated by the FDA, mifepristone is the only one that requires an in-person pickup.
By Valérie Gauriat
In front of one of Warsaw's main hospitals, an ominous van is parked. Its sides are covered in an image of what is allegedly a dead fetus. It's a message from anti-abortion groups to one of the capital’s few facilities that still perform pregnancy terminations.
A recent ruling by the Constitutional Tribunal has just toughened one of the most restrictive abortion laws in Europe. Terminations in Poland were once only allowed in cases of rape, incest, danger to the mother's health or life, serious defects of the fetus or incurable disease. The new amendments mean that last option is now prohibited.
FDA’s regulation of medication abortion must be guided by science, not politics.
Jan 26, 2021
Erectile dysfunction drugs have a mortality rate nearly four times greater than Mifeprex, otherwise known as the abortion pill. But despite being less safe, erectile dysfunction drugs are available over the counter at pharmacies. Mifeprex, by contrast, remains one of the U.S. Food and Drug Administration’s (FDA) most heavily regulated drugs—and is even more restricted than fentanyl, an opioid.
This divergence in the regulation of Mifeprex compared to other drugs stems from highly politicized debates over abortion and reproductive rights. FDA’s regulation of Mifeprex, however, should be informed by science, not politics. Despite a demonstrated safety record, Mifeprex remains subject to restrictions that significantly limit its availability to consumers—restrictions that should be reserved for the most dangerous of drugs.